Article

Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy: Impact of Intramesorectal Distribution and Residual Micrometastatic Involvement.

Departments of *General and Visceral Surgery ‡Medical Statistics §Pathology ∥Radiation Oncology and Radiotherapy, University Medical Center Göttingen †Department of Pathology, Medical Care Unit Göttingen, Göttingen ¶Department of Radiotherapy and Oncology, University of Frankfurt, Frankfurt/Main, Germany.
The American journal of surgical pathology (Impact Factor: 4.59). 08/2013; 37(8):1283-1289. DOI: 10.1097/PAS.0b013e3182886ced
Source: PubMed

ABSTRACT After neoadjuvant chemoradiation (CRT), the pathologic determined lymph node (LN) status is the most important prognostic factor in rectal cancer patients. Here we assessed the prognostic impact of residual LN micrometastases (<0.2 cm) and the intramesorectal distribution of LN metastases.
Surgical specimens from 81 patients with cUICC II/III rectal cancer undergoing neoadjuvant CRT and total mesorectal excision within the German Rectal Cancer Trial CAO/ARO/AIO-04 were prospectively evaluated. The entire mesorectal compartment was paraffin embedded and screened microscopically. The number and distribution of mesorectal LN macrometastases and micrometastases were correlated with disease-free (DFS) and cancer-specific overall survival (CSS).
A total of 2412 LNs were detected (mean 29.8±13.7). Twenty-five patients had residual LN metastases (ypN+). The incidence of metastases in the peritumoral mesorectum was higher (7.7%) than that proximal to the tumor (1.5%), whereas no metastases were identified below the tumor level. Patients with both proximal and peritumoral involvement showed a significantly reduced CSS (hazard ratio=5.4; P<0.05). Fourteen patients with ypN+ status (56%) had micrometastases, 9 patients (36%) had only micrometastatic involvement. Patients with nodal macrometastases had a reduced DFS (P<0.01) and CSS (P<0.005) as compared with ypN0 patients, whereas residual micrometastases had no influence on survival.
Despite the high incidence of residual LN micrometastases they did not seem to have a prognostic impact in this series. Micrometastases might indicate responsive tumors to CRT with a more favorable biology. The intramesorectal distribution of LN metastases had a prognostic impact and should be validated in further studies.

1 Follower
 · 
83 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: For patients with locally advanced rectal cancer, the accuracy rates of preneoadjuvant therapy nodal staging and potential nodal downstaging make the prognostic significance of nodal status unclear. We therefore sought to review our experience in order to better understand the impact of clinical and pathologic nodal status upon patient outcomes. 174 patients were identified as having undergone neoadjuvant chemoradiation and resection for rectal cancer. For analytic purposes, patients were grouped into four nodal categories (uN (0)center dot pN (0), uN (0)center dot pN (+), uN (+) center dot pN (0), and uN (+) center dot pN (+)). Univariate and multivariate analyses were performed. 104 men and 70 women of median age 60 years (29-85 years) were followed for a median of 31 months (1-121 months). Nodal staging was available for 129 patients, with a median of 8 lymph nodes (range 0-39) evaluated. Disease recurred in 3 of 41 (7 %) uN (0) center dot pN (0), 10 of 52 (20 %) uN (+)center dot pN (0), 7 of 18 (41 %) uN (0)center dot pN (+), and 6 of 17 (35 %) uN (+)center dot pN (+) patients. Those patients having nodal downstaging (uN (+)center dot pN (0)) experienced superior overall survival (p = 0.03). Only pathologic nodal status was a significant predictor of both disease-free and overall survival in multivariate modeling. Adjuvant chemotherapy did not impact disease-free or overall survival for patients with pN0. Pathologic nodal status may represent a superior predictor of survival for patients with local advanced rectal cancers. Our findings may have potential implications for the application of adjuvant therapy.
    International Journal of Colorectal Disease 06/2014; 29(9). DOI:10.1007/s00384-014-1917-8 · 2.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Total mesorectal excision (TME) is the current optimal surgical treatment for patients with rectal carcinoma. A complete TME is related to lower local recurrence rates and increased patient survival. Many confounding factors in the patient's anatomy and prior therapy can make it difficult to obtain a perfect plane, and thus a complete TME. The resection specimen can be thoroughly evaluated, grossly and microscopically, to identify substandard surgical outcomes and increased risk of local recurrence. Complete and accurate data reporting is critical for patient care and helps surgeons improve their technique.
    Clinics in Colon and Rectal Surgery 03/2015; 28(1):43-52. DOI:10.1055/s-0035-1545069